A hybrid design for dose‐finding oncology clinical trials

Identifying the maximum tolerated dose (MTD) and recommending a Phase II dose for an investigational treatment is crucial in cancer drug development. A suboptimal dose often leads to a failed late‐stage trial, while an overly toxic dose causes harm to patients. There is a very rich literature on tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Jason J. Z., Zhou, Feng, Zhou, Heng, Petruzzelli, Lilli, Hou, Kevin, Asatiani, Ekaterine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Innovative Tools and Methods
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084431/
https://www.ncbi.nlm.nih.gov/pubmed/35802470
http://dx.doi.org/10.1002/ijc.34203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084431/
https://www.ncbi.nlm.nih.gov/pubmed/35802470
http://dx.doi.org/10.1002/ijc.34203

Ejemplares similares